However, like other GLP-1 receptor agonists, it may not be suitable for individuals with a history of thyroid cancer, certain endocrine disorders, or severe gastrointestinal conditions
A phase 2 trial comparing semaglutide with placebo in patients with type 2 diabetes on basal insulin
The data will be published daily to a public dashboard to streamline the FDA's reporting systems and increase the frequency of reporting to aid in faster identification of safety signals
Participants in a 68-week study lost an average of about 34 pounds while on 2.4 mg of semaglutide
Drugs such as liraglutide, semaglutide, dulaglutide, and the dual GLP-1/GIP receptor agonist tirzepatide demonstrate robust efficacy for weight reduction and glycemic optimization
Semaglutide and newer GLP-1 drugs help people lose substantially more weight than diet and exercise alone, primarily through reducing peoples appetite and cravings